Modeling Effect of a γ-Secretase Inhibitor on Amyloid-β Dynamics Reveals Significant Role of an Amyloid Clearance Mechanism

• Published in: Bulletin of mathematical biology 2011, Vol.73 (1), p.230-247
• Main Authors: Das, Raibatak, Nachbar, Robert B, Edelstein-Keshet, Leah, Saltzman, Jeffrey S, Wiener, Matthew C, Bagchi, Ansuman, Bailey, James, Coombs, Daniel, Simon, Adam J, Hargreaves, Richard J, Cook, Jacquelynn J
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - etiology; Alzheimer Disease - metabolism; Alzheimer's disease; Amyloid beta-Peptides - blood; Amyloid beta-Peptides - cerebrospinal fluid; Amyloid beta-Peptides - metabolism; Amyloid Precursor Protein Secretases - antagonists & inhibitors; Animals; Cell Biology; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - pharmacokinetics; Enzyme Inhibitors - pharmacology; Humans; Life Sciences; Macaca mulatta; Mathematical and Computational Biology; Mathematical Concepts; Mathematics; Mathematics and Statistics; Models, Animal; Models, Biological; Original Article; Solubility
• ISSN: 0092-8240; 1522-9602
• DOI: 10.1007/s11538-010-9540-5

Aggregation of the small peptide amyloid beta (Aβ) into oligomers and fibrils in the brain is believed to be a precursor to Alzheimer's disease. Aβ is produced via multiple proteolytic cleavages of amyloid precursor protein (APP), mediated by the enzymes β- and γ-secretase. In this study, we examine the temporal dynamics of soluble (unaggregated) Aβ in the plasma and cerebral-spinal fluid (CSF) of rhesus monkeys treated with different oral doses of a γ-secretase inhibitor. A dose-dependent reduction of Aβ concentration was observed within hours of drug ingestion, for all doses tested. Aβ concentration in the CSF returned to its predrug level over the monitoring period. In contrast, Aβ concentration in the plasma exhibited an unexpected overshoot to as high as 200% of the predrug concentration, and this overshoot persisted as late as 72 hours post-drug ingestion. To account for these observations, we proposed and analyzed a minimal physiological model for Aβ dynamics that could fit the data. Our analysis suggests that the overshoot arises from the attenuation of an Aβ clearance mechanism, possibly due to the inhibitor. Our model predicts that the efficacy of Aβ clearance recovers to its basal (pretreatment) value with a characteristic time of >48 hours, matching the time-scale of the overshoot. These results point to the need for a more detailed investigation of soluble Aβ clearance mechanisms and their interaction with Aβ-reducing drugs.